Our commitment to transforming the lives of people with rare diseases drives what we do

Insmed Incorporated (NASDAQ: INSM) is a biopharmaceutical developing a proprietary advanced liposomal pulmonary technology in areas of high unmet need with site-specific treatment of serious lung diseases in cystic fibrosis (CF) patients, Pseudomonas aeruginosa lung infections and non-tuberculous mycobacteria (NTM). Its lead compound ARIKACE® (liposomal amikacin for inhalation) showed positive pivotal phase III results in patients with NTM.

  • CEO Will Lewis
  • Industry Biotech